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Vascular development involves a highly orga-
nized sequence of events, such as vasculogene-
sis and angiogenesis. During blood vessel 
formation, the fi  rst step is the diff  erentiation of 
endothelial cells (ECs) and mural cells (MCs), 
such as smooth muscle cells (SMCs) and 
  pericytes, from vascular stem cells expressing 
  vascular endothelial growth factor (VEGF) 
receptor 2 (Flk-1; reference 1). This is followed 
by proliferation and migration of ECs and 
eventual formation of endothelial tubes result-
ing in formation of the primary vascular plexus. 
This event is termed vasculogenesis. Subse-
quently, for the adjustment of tissue-specifi  c 
oxygen and nutrient supply, the primary vascu-
lar plexus is remodeled by sprouting or non-
sprouting angiogenesis, fusion of vessels, and 
regression. Finally, the maturation of nascent 
vasculature is accomplished by recruitment and 
adhesion of MCs to ECs. This fi  nal step allows 
generation of an extracellular matrix and spe-
cialization of the vessel wall for structural sup-
port and regulation of vessel function (2).
It is clear that maintenance of cell adhesion 
between ECs and MCs is necessary to safeguard 
against pathogenic malformation as well as ag-
ing because it is well known that pericyte loss 
leads to abnormal blood vessel formation in 
many diseases, such as diabetic microangiopa-
thy, cancer, venous malformation, and so on 
(3, 4). Therefore, to address the development 
of therapy for such diseases, it is important to 
investigate the development of MCs and ma-
nipulate MCs in vitro for potential use in re-
generation therapy and research into molecular 
targets of drugs.
Emerging evidence indicates that platelet-
derived growth factor (PDGF)-B plays a criti-
cal role in the recruitment of MCs to newly 
formed vessels (5, 6). VEGF and PDGF-B are 
likely to participate in regulating both MC and 
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EC survival. PDGF-B induces VEGF expression in SMCs 
and cultured pericytes, and VEGF is known to protect ECs 
from apoptosis (7, 8). Angiopoietin (Ang)-1, a ligand for 
Tie2 expressed on ECs, is produced from MCs and promotes 
selective cell adhesion between MCs and ECs, which is me-
diated by the activation of integrin on ECs (9, 10). During 
angiogenesis, prolonged expression of Ang-2 from ECs in-
hibits MC adhesion to ECs resulting in regression of newly 
developed blood vessels (11). Genetic ablation of Ang-1 (9) 
or Tie2 (12, 13) and overexpression of Ang-2 (14), an antag-
onist for Ang-1, in ECs of mice lead to dissociation between 
MCs and ECs. These observations strongly suggest a central 
role for the Tie2–Ang system in the stabilization and destabi-
lization of blood vessels.
Although the molecular mechanism of adhesion between 
MCs and ECs is gradually becoming better understood, little 
is known about how MCs facilitate the angiogenic sprout. In 
the larger vessels, mesenchymal cells surrounding ECs diff  er-
entiate into MCs, mainly SMCs, which then adhere to ECs. 
On the other hand, in the case of newly developed capillaries 
that sprout from preexisting vessels, the common view is that 
MC recruitment lags behind that of ECs in the angiogenic 
process. This view is based on studies of retinal angiogenesis 
(15). However, an opposing view states that in the corpus lu-
teum, MCs are the fi  rst vascular cells to migrate into the 
  hypoxic region and might promote migration of ECs (16). 
Thus, the relationship between ECs and MCs may be diff  er-
ent in various angiogenic contexts based on the origin of 
MCs. There are four possible origins for MCs, namely, 
  mesenchymal cells, ECs, neural crest cells, and adult BM he-
matopoietic stem cell (HSC) populations (17). However, in 
the case of pericytes phenotypically overlapping with SMCs, 
the origin is not defi  ned yet. Pericytes are a source of SMCs 
as well as fi   broblasts and have been reported to show 
self-  renewal activity, suggesting that they may be a stem cell 
population (18).
We previously reported that HSCs migrate into the avas-
cular area and promote sprouting angiogenesis by producing 
Ang-1, a chemoattractant for ECs (19). Because Ang-1 pro-
duction and self-renewal activity are common features of 
HSCs and pericytes, and moreover, HSCs have a capacity to 
adhere with ECs (10), it is possible that in the physiologic sit-
uation the HSC population diff  erentiates into SMCs through 
the pericyte lineage.
Recently, it was reported that the HSC population des-
ignated as Lin−c-Kit+Sca-1+ in the BM of adult mice diff  er-
entiates into SMCs and are incorporated into blood vessels 
in pathologic situations, such as atherosclerosis, postangio-
plasty restenosis, and graft vasculopathy (20). However, 
whether the derivation of MCs from the HSC population is 
induced in normal physiological conditions or not, the hier-
archical diff  erentiation pathway of HSCs into MCs is not yet 
fully clear. Therefore, in this study, we investigated the role 
of HSCs in the stability of blood vessels using acute myeloid 
leukemia 1 (AML1) null embryos, which lack defi  nitive-
type HSC development. We studied the molecular and en-
vironmental cues necessary for the derivation of MCs from 
the HSC population. Using mice, we report that HSCs 
  actually change their pathway of diff  erentiation into a MC 
population through a CD45+CD11b+ cell lineage in vitro 
and in vivo, and play an important role for the stabilization 
of newly developed blood vessels in physiologic and patho-
logic situations.
RESULTS
HSC population differentiates into MCs 
during embryogenesis
We previously reported that HSCs appear in the brain ecto-
dermal layer during embryogenesis before the appearance of 
ECs to form the capillary network at this site (19). These 
HSCs produce Ang-1, promote sprouting angiogenesis from 
the peri-ectodermal vascular plexus, and fi  nally locate near 
newly developed blood vessels. Without HSC development 
in AML1 mutant embryos, vascular network formation in 
the ectodermal layer was insuffi   cient and hemorrhage oc-
curred from the disorganized blood vessels at the embryonic 
day 12.5 (E12.5) stage (21, 22). Based on these observations, 
we hypothesized that the HSC population might be associ-
ated with the stability of blood vessels. Stability or maturation 
of blood vessels is closely related to MC attachment to ECs. 
Therefore, we fi  rst studied the development of MCs in the 
ectodermal layer focusing on the localization of HSCs or 
  hematopoietic progenitor cells (HPCs) using wild-type and 
AML1 mutant embryos.
At E10.5, the c-Kit+ HSC/HPC population is located 
in the proximity of ECs in the brain ectodermal layer (Fig. 
1 a); however, in this stage, we could not detect the smooth 
muscle actin (SMA)+ or desmin+ MCs (Fig. 1 b; desmin 
not depicted). 1 d later at E11.5, we observed that some 
HSCs/HPCs adhered to ECs (Fig. 1 d) and MCs adhering 
to ECs also fi  rst appeared in this stage (Fig. 1 e). At E12.5, 
adhesion of HSCs to ECs was still observable (Fig. 1 g) and 
most of the capillaries contained MCs (Fig. 1 h). On the 
other hand, in the case of AML1 mutant embryos, the HSC 
population marked by c-Kit (not depicted) and MCs (Fig. 1, 
c and f) could not be detected in the ectodermal layer at 
E10.5 and E11.5.
Based on these observations, it appears that the HSC/
HPC population diff  erentiates into MCs and promotes the 
stability of blood vessels. To confi  rm this observation, we at-
tempted to clarify whether a purifi  ed HSC population in 
  vitro could diff  erentiate into MCs or not. As showed in Fig. 1 
i, we sorted the HSC/HPC population designated as Lin−
c-Kit+ among CD45+ hematopoietic cells (HCs) from the 
ectodermal layer of E12.5 embryos and cultured them on 
fi  bronectin-coated culture plates in the presence of PDGF-BB.
From 104 HSCs, only a small number of cells (0.12 ± 0.02%, 
n = 3) were found to be able to adhere to the culture plate 
and produce colonies; however, almost all colonies contained 
PDGFRβ+ (Fig. 1 j) and SMA+ (Fig. 1, k and l) cells. 
As previously reported in the adult (23), we found that ECs 
expressing CD31/PECAM-1 or Flk-1 also developed from JEM VOL. 203, April 17, 2006  1057
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the HSC population in the embryo in the presence of PDGF-
BB and VEGF (Fig. 1, k and l).
Environmental molecular cues are required 
for the differentiation of MCs from the HSC population
During early embryogenesis, HSCs develop in the AGM 
region surrounded by the aorta, gonads, mesonephros, 
dorsal aorta, and the omphalomesenteric artery, migrate to 
the fetal liver for their expansion, and then widely spread 
into the whole body. As has been reported, the HSC pop-
ulation has a plasticity to diff  erentiate into cells other than 
HCs (24–26). However, whether such plasticity occurs 
during embryogenesis is not clear. If such transdiff  erentia-
tion is observed during embryogenesis, diff  erentiation of 
MCs from HSCs seems to be a natural course of the pro-
grammed diff   erentiation pathway for organogenesis. To 
fi  nd out whether HSCs located in the regions other than 
the brain can also diff  erentiate into MCs, the HSC popula-
tion was sorted from E12.5 fetal liver as a major hem-
atopoietic site, fractionated using identical markers 
(Lin−c-Kit+CD45+; Fig. 2 a), and cultured in the same 
culture condition as described above. Although a small 
number of HSCs adhered to the culture plate, we could 
not detect SMA+ (Fig. 2 b) nor desmin+ (not depicted) 
MCs. However, when HSCs/HPCs from fetal liver were 
cocultured with cells from the brain ectodermal layer of 
the E12.5 embryo, they diff  erentiated into MCs (Fig. 2 d) 
as well as ECs (Fig. 2 e). These fi  ndings suggested that the 
environmental molecular cues produced from cells com-
posing the ectodermal layer must regulate the diff  erentia-
tion of HSCs/HPCs into MCs. Among several growth 
factors examined, we found that TGF-β or bFGF has a 
Figure 1.  HSC population in the embryonic brain can give rise to 
MCs. (a–h) Brain sections at E10.5 (a–c), E11.5 (d–f), and E12.5 (g and h) 
from wild-type mice (a, b, d, e, g, and h), and AML1 mutant mice (c and f) 
were dual stained with anti–c-Kit mAb (red) and anti-CD31 mAb (dark 
blue; a, d, and g) or with anti-SMA mAb (brown) and anti-CD31 (dark 
blue; b, c, e, f, and h). Inset (e and h) shows high power view indicated by 
box. Bar in panel a, 50 μm. (i) FACS analysis of HSC/HPC population exist-
ing in the mouse brain at E12.5. The number in the top-right quadrant 
indicates the percentage of c-Kit+ CD45+ cells among Lin− cells. The data 
is representative of three independent experiments. (j–l) Phenotype of 
cultured HSC/HPC populations in vitro. The HSC/HPC population indicated 
by the box in panel i was cultured on fi  bronectin-coated culture plates for 
14 d and stained with anti-CD31 (dark blue; j), anti-SMA mAb (brown; 
k and l), anti–PECAM-1 mAb (dark blue; k), or anti–Flk-1 mAb (dark blue; l). 
Arrows (k and l) indicate cells expressing CD31 or Flk-1, respectively. Bar 
in panel j, 30 μm.
Figure 2.  Induction of differentiation of the HSC/HPC population 
existing in the fetal liver into MCs. (a) FACS analysis of the HSC/HPC 
population existing in the mouse fetal liver at E12.5. The number in the 
top-right quadrant indicates the percentage of c-Kit+ CD45+ cells among 
Lin− cells. The data is representative of three independent experiments. 
(b–f) The HSC/HPC population indicated by the box in panel a was cul-
tured with or without cells from the brain in the presence of PDGF-BB 
and VEGF. (b) HSCs/HPCs alone cultured for 14 d were stained with anti-
SMA mAb. (c) Schematic presentation of the coculture system with HSCs/
HPCs from the fetal liver and cells from the brains of E12.5 mouse 
embryos. (d and e) HSCs/HPCs cultured with cells from the brain were 
stained with anti-SMA mAb (brown; d) or anti–CD31 mAb (dark blue; e). 
Bar in panel e, 30 μm. (f) Growth factors affecting the induction of HSCs/
HPCs into MCs or ECs. HSCs/HPCs indicated by the box in panel a were 
cultured in the basic medium alone (EBM2), in EBM2 with 0.5 or 5 ng/ml 
TGF-β or 10 ng/ml bFGF, or with cells from the brain as described above. 
Cells adhering to culture plates were stained with anti–CD31 mAb or anti-
SMA mAb, and the number of positively stained cells were determined. 
Results are expressed as the mean ± SD (n = 5).1058  VESSEL MATURATION BY HEMATOPOIETIC CELLS | Yamada and Takakura
weak capacity to promote the diff  erentiation of fetal liver 
HSCs into MCs (Fig. 2 f).
Differences between CD45+CD11blow cells 
and CD45+CD11bhigh cells for development into MCs
In the steady-state in the normal animal, mononuclear cells 
existing in peripheral blood (PB) barely diff  erentiate  into 
MCs or ECs if isolated and cultured under the same culture 
conditions as was used for HSCs/HPCs from the brain of 
embryos (not depicted). Therefore, appropriate molecular 
signals may change the fate of HSCs into MCs in the adult as 
well as in the embryo. To address this issue, we induced hyp-
oxia in the hind limb of mice by ligation of the femoral artery 
and observed whether the HCs in the PB can diff  erentiate 
into MCs. The monocyte/macrophage lineage has been sug-
gested to diff  erentiate into ECs (27, 28) and, moreover, MCs 
and ECs are thought to develop from common progenitors 
(1); therefore, at fi  rst, we used CD45 and CD11b as markers 
of vascular progenitor cells.
FACS analysis showed that there were three populations 
among CD45+ cells, namely, CD11b−, CD11blow, and 
CD11bhigh in hypoxia-induced PB (Fig. 3 A, a). The 
CD45+CD11blow (CD11blow) cells expressed Sca-1 strongly 
and c-Kit weakly; however, CD45+CD11bhigh (CD11bhigh) 
cells expressed both of them at a low level (Table I). More-
over, analysis of the CFUs in culture (CFU-c) revealed that 
CD11blow cells have a higher capability to form CFU-
GEMM, BFU-E, and CFU-GM compared with CD11bhigh 
cells (Table S1, available at http://www.jem.org/cgi/content/
full/jem.20050373/DC1). These observations suggested that 
phenotypically, the CD11blow population   belongs to the 
HSC/HPC population and the CD11bhigh population be-
longs to the mature monocyte/macrophage population, and 
they highly expressed CD11c and CD14 (Table I) as previ-
ously reported (29, 30).
Next, we cultured CD11blow, CD11bhigh, and CD45+
CD11b− (CD11b−) cells from hypoxia-induced PB in the 
same culture condition as described above. Both CD11blow 
and CD11bhigh cells produced SMA+ MC lineage cells (Fig. 
3 A, b and c). Although the EC lineage derived from both 
CD11bhigh and CD11blow populations expressed CD31 
strongly (not depicted), the EC lineage from the CD11bhigh 
population expressed Flk-1 very weakly compared with that 
from the CD11blow population (Fig. 3 A, c). We confi  rmed 
that MCs or ECs derived from CD11b+ cells expressed other 
vascular cell–specifi  c markers, PDGFRβ and desmin or VE-
cadherin and vWF, respectively (Fig. S1, available at http:// 
www.jem.org/cgi/content/full/jem.20050373/DC1). On 
the other hand, CD11b− cells diff  erentiated into neither   
Flk-1+/CD31+ cells nor SMA+ cells (not depicted). We then 
examined the time of appearance of vascular progenitor cells 
in CD11blow and CD11bhigh populations abundantly after is-
chemia was induced. For this purpose, sorted 105 CD11blow 
and CD11bhigh populations of PB on days 1, 3, and 7 after 
ischemia was induced were cultured on a fi  bronectin-coated 
dish. After 14 d of culturing, we evaluated EC and SMC 
development from two populations. We detected CD31+ 
Figure 3.  CD45+CD11b+ cells existing in the PB under the hypoxia 
differentiate into MCs. (A) FACS analysis of HCs in the PB of mice. Mono-
nuclear cells dual stained with anti-CD45 mAb and anti-CD11b mAb under 
normoxic (steady-state) conditions and ischemia. The numbers indicate the 
fraction of the cells in each box in the total mononuclear cells in the PB. Cells 
fractionated as CD45+CD11blow (b) and CD45+CD11bhigh (c) were sorted sepa-
rately and cultured in the presence of VEGF and PDGF-BB. Cultured cells on 
fi  bronectin-coated plates were stained with anti-SMA mAb (brown) and anti–
Flk-1 mAb (dark blue). Bar, 25 μm. (B) Development of CD31+ ECs and SMA+ 
SMCs from CD11bhigh and CD11blow cells in the PB of mice in which ischemia 
had been induced by ligation of the femoral artery. CD11+ cells were collected 
from the PB on days 1,3, and 7 after ischemia was induced and cultured for 
14 d. (C) Time course of EC (left) and MC (right) development from 
CD11blow cells (green square) or CD11bhigh cells (red circle). Results are 
expressed as the mean ± SD (n = 5). (D) Limiting dilution analysis of CD11blow 
cells (green square) or CD11bhigh cells (red circle) for differentiation into ECs 
(a) and MCs (b). The frequency of cell differentiation into ECs or MCs is 
depicted on the graph based on the Poisson analysis.
Table I.  Expression of monocyte makers in CD11b subpopulation
CD11b− (%) CD11blow (%) CD11bhigh (%)
c-Kit 0.5 ± 0.1 2.0 ± 0.3 0.7 ± 0.3
Sca-1 50.6 ± 2.8   94.3 ± 6.5   13.7 ± 1.6  
CD11a 84.6 ± 6.8   83.7 ± 10.5 95.0 ± 9.7  
CD11c 0.4 ± 0.1 3.2 ± 1.3 71.5 ± 8.6  
CD14 3.3 ± 1.1 7.0 ± 1.8 77.4 ± 9.2  
CD18 5.5 ± 1.8 25.2 ± 5.6   95.1 ± 10.1JEM VOL. 203, April 17, 2006  1059
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EC and SMA+ SMC development abundantly in the cul-
tures of both CD11bhigh and CD11blow populations from PB 
1 and 3 d after ischemia; however, the number of ECs and 
SMCs developed from CD11bhigh and CD11blow populations 
on day 7 after ischemia decreased (Fig. 3 B). This indicated 
that mobilization of vascular progenitor cells designated as 
CD45+CD11blow or CD45+CD11bhigh in PB was induced 
in the early stage of ischemia. Therefore, in the following 
experiments, we used CD45+CD11b+ (CD11b+) cells from 
PB on day 3 after ischemia was induced.
To determine the time course of development and growth 
of the MC and EC lineages, we cultured CD11bhigh and 
CD11blow populations for 28 d (Fig. 3 C). CD11bhigh cells 
adhering to culture plate showed a spindle-like shape within 
24 h and produced a large number of CD31+ cells at day 7; 
however, the number of CD31+ cells decreased gradually and 
this was caused by apoptosis of the ECs (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20050373/DC1). 
In contrast, CD11blow cells formed a spindle-like shape 
around day 7 and the number of CD31+ cells gradually 
increased (Fig. 3 C). Interestingly, the growth kinetics of 
MC development is much higher for CD11blow cells than 
CD11bhigh cells (Fig. 3 C).
Next, we estimated the incidence of EC or MC develop-
ment from CD11blow or CD11bhigh cells by limiting dilution 
analysis and found that 1 out of 560 CD11blow cells and 1 out 
of 965 CD11bhigh cells can diff  erentiate into ECs, whereas, 1 
out of 9,750 CD11blow cells and 1 out of 16,500 CD11bhigh 
cells diff  erentiate into MCs. The low incidence of MC or EC 
development from CD11blow and CD11bhigh cells is likely 
due to the limitation of the in vitro culture system. These 
fi  ndings suggested that CD11blow cells are more immature 
than CD11bhigh cells and have a higher potential to diff  erenti-
ate into MCs. Additionally, in sham-operated mice, i.e., un-
der normoxic conditions, the FACS staining profi  le of CD45 
and CD11b markers in PB was similar to that under ischemic 
conditions (Fig. 3 A, a). However, we determined that 1 
among 4,380 or 1 among 68,200 CD11blow cells diff  erenti-
ated into ECs or MCs, respectively, and that 1 among 5,250 
or 1 among 89,100 CD11bhigh cells diff  erentiated into MCs 
or ECs, respectively. Collectively, these results suggested that 
cells from the CD11b+ population are capable of diff  erenti-
ating into MCs in adulthood and such diff  erentiation capacity 
is induced by some molecular cues that exist in pathologic 
conditions such as ischemia.
The contribution of CD45+CD11b+ cells in ischemic limbs
We studied the mechanism whereby CD11b+ cells con-
tributed to the improvement of ischemia in the hind limbs. 
To achieve this, CD11b−, CD11blow, and CD11bhigh cells 
were isolated from mice that had ischemia induced in the 
hind limbs and were injected into the thigh muscles of the 
hind limbs of other mice in which ischemia had been in-
duced by occlusion of the femoral arteries. 14 d after injec-
tion of the cells, we dissected the adductor and gastrocnemius 
muscle and evaluated the collateral artery size and capillary 
number. The collateral artery size and the CD31+ capillary 
number in the adductor muscle increased after injection of 
CD11blow or CD11bhigh cells (Fig. 4 A, b and c) compared 
with those of mice injected with CD11b− cells (Fig. 4 A, 
a, d, and e). Moreover, improvement of blood fl  ow in the 
upper limbs by injection of CD11blow or CD11bhigh cells 
enhanced capillary formation in the gastrocnemius muscles 
and inhibited the atrophy that was observed in the gastroc-
nemius muscle injected with CD11b− cells (Fig. 4 B). 
These results indicated that CD11blow and CD11bhigh cells 
equally enhanced capillary formation and improved ische-
mic damage.
Figure 4.  Contribution of CD45+CD11b+ cells for neovasculariza-
tion. CD45+CD11b− or CD45+CD11b+ cells were sorted as described in 
Fig. 3 A from the PB of mice in which ischemia had been induced by liga-
tion of the femoral artery. Cells thus obtained were injected into the is-
chemic thigh muscles of other mice that had their femoral arteries ligated 
and resected. (A) Evaluation of the size of collateral artery and the vessel 
number in the adductor muscle. Sections of adductor muscle injected 
with CD45+CD11b− (a), CD11blow (b), or CD11bhigh (c) cells were stained 
with anti-CD31 antibody. Bar in panel c, 50 μm. (d) Size of collateral ar-
tery counted in fi  ve random fi  elds. (e) Number of capillaries counted in 
fi  ve random fi  elds. (B) Evaluation of the number of capillaries in the gas-
trocnemius muscles. Sections of adductor muscle injected with 
CD45+CD11b− (a), CD11blow (b), or CD11bhigh (c) cells were stained with 
anti-CD31 antibody. Bar in panel c, 50 μm. (d) Number of capillaries 
counted in fi  ve random fi  elds.1060  VESSEL MATURATION BY HEMATOPOIETIC CELLS | Yamada and Takakura
The mechanism of recruitment of CD11b population 
into ischemic limbs
To determine whether intravenous injection of CD11b+ 
cells can lead to selective homing of these cells to the ische-
mic limb, we injected from the tail vein CD11b−, CD11blow, 
or CD11bhigh cells derived from ischemia-induced green 
mice (31) that express GFP ubiquitously into ischemia-in-
duced wild-type mice and then observed the localization of 
the injected CD11b subpopulation in the adductor muscles 
after 3 d. The results showed that CD11b− cells did not ap-
pear in the ischemic adductor muscle (Fig. 5 A, a); however, 
CD11blow and CD11bhigh cells were randomly distributed 
around the vessels in the ischemic limb (Fig. 5 A, b and c).
CD11bhigh cells tended to be more abundant compared with 
CD11blow cells, but this diff  erence was not statistically signifi  -
cant (Fig. 5 A, d). Moreover, we confi  rmed that endogenous 
CD11b+ cells were recruited into and adhered to the vessel 
wall in the ischemic limbs (Fig. S3, available at http://www. 
jem.org/cgi/content/full/jem.20050373/DC1).
Next, we examined the mechanisms that support the re-
cruitment of CD11b cells to ischemic limbs. We extracted 
mRNA from the nonischemic and ischemic muscle to iden-
tify the critical chemokines, and we used CD11b−, CD-
11blow, and CD11bhigh cells in the PB of ischemia-induced 
mice to identify the chemokine receptors for the recruitment 
of these cells to the ischemic site. Among the various chemo-
kines, CCL2 and SDF-1α are major chemokines in the 
monocyte and HSC lineages (32), and VEGF-A is also known 
as one of the most potent chemoattractant proteins in those 
fractions (23). Therefore, we investigated the role of these 
factors and their receptors. The results indicated that CCL2, 
SDF-1α, and VEGF-A were up-regulated in ischemic mus-
cles and their receptors; namely, CCR-2, CXCR4, and 
VEGFR-1 were detected on CD11blow and CD11bhigh frac-
tions but not on CD11b− fractions (Fig. 5 B).
In vivo incorporation of CD45+CD11b+ cells 
into vascular cells
Next, we investigated the role of CD11b+ cells in the 
  process of neovascularization in vivo. To achieve this, 
CD11b+ or CD11b− cells isolated from green mice that 
had ischemia induced in the hind legs were injected into 
the thigh muscle of the hind limbs of mice in which ische-
mia had been induced by occlusion of the femoral artery. 
3 d after injection of cells, GFP+ cells were seen to be 
randomly distributed in the ischemic muscle. However, 
after 14 d of transplantation, most GFP+ cells remaining in 
the ischemic muscle were associated with blood vessels. As 
observed in vitro, CD11b+ cells had the potential to dif-
ferentiate into ECs as indicated by the incorporation of 
GFP+ cells into newly developed blood vessels as ECs 
(Fig. 6 A, a–c).Moreover, GFP+ cells were seen to adhere 
to ECs and expressed PDGFRβ (Fig. 6 B, a–c) and SMA 
(not depicted) in the ischemic tissues, suggesting that 
CD11b+ cells could diff  erentiate into MCs (Fig. 6 B, a–c). 
As observed in the in vitro experiments, CD11b− cells did 
not contribute to ECs or MCs in the ischemic muscle 
(Fig. 6 A, d–f, and B, d–f).
Additionally, we compared the long-term contribution 
of transplanted CD11bhigh or CD11blow cells for vascular cells. 
The number of CD11bhigh cells that formed ECs and MCs 
after 6 mo of transplantation decreased signifi  cantly compared 
with that after 2 wk of transplantation. On the other hand, 
although the number of ECs or MCs decreased, CD11blow 
cells were capable of forming vascular cells for a longer   period 
than CD11bhigh cells (Fig. 6 C).
To assess functional recovery, we observed the behavior 
of the mice. In the fi  rst 2 wk, movement of ischemic legs in 
mice injected with CD11bhigh cells declined slightly com-
pared with that of mice injected with CD11blow cells. How-
ever, such impairment was gradually reduced and movement 
of legs became comparable between CD11bhigh-injected mice 
and CD11blow-injected mice after 1 mo. Although the density
of blood vessels in the ischemic muscles of CD11bhigh cell–
  injected mice was nearly 15% lower relative to that of mice 
injected with CD11blow cells after 6 mo of transplantation 
Figure 5.  Recruitment of the CD11b subpopulation into ischemic 
lesions. (A) Sections of adductor muscle from mice in which ischemia had 
been induced by ligation of the femoral artery and that were injected intra-
venously with CD45+CD11b−GFP+ (a), CD11blowGFP+ (b), or CD11bhighGFP+ 
(c) cells were studied. Arrows indicate GFP+ cells. (d) Number of GFP+ 
cells counted in fi  ve random fi  elds. (B) RT-PCR analysis of CCL2, SDF-1, 
and VEGF-A expression in ischemic muscle (left, ischemic M) and nonisch-
emic muscle (non-ischemic M) or of CCR2, CXCR4, and VEGFR-1 expres-
sion in CD11b−, CD11blow, and CD11bhigh cells (right). BM cells (BMCs) were 
used as positive control.JEM VOL. 203, April 17, 2006  1061
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(not depicted), we concluded that the diff  erence in the po-
tential of CD11bhigh and CD11blow cells to restore the func-
tion of ischemic muscle was not signifi  cantly diff  erent.
CD45+CD11blow cells can promote nonleaky blood vessel 
formation through Ang-1
Next, we examined how CD11blow and CD11bhigh cells af-
fected the vascular phenotype. CD11blow cells express c-Kit 
and Sca-1 and are thought to belong to the HSC/HPC popu-
lation. This is in contrast to CD11bhigh cells, which are the so-
called mature macrophages or monocytes. Interestingly, we 
found that postoperatively, in the mice injected with CD11bhigh 
cells, the open incision persisted for 14 d with   eff  usion of in-
fi  ltrate due to the trauma. On the other hand, such infi  ltration 
was not observed in mice injected with CD11blow cells, and 
the incision closed within 14 d (not depicted).
Based on these observations, we hypothesized that 
CD11bhigh or CD11blow cells produce molecules that regulate 
permeability. It was previously reported that VEGF-medi-
ated hyperpermeability was inhibited by Ang-1 (33). Fur-
thermore, we reported that the HSC population produces 
Ang-1 strongly and lack of HSCs in AML1-defi  cient mice 
resulted in the rupture of blood vessels during embryogenesis 
(19). The phenotype of CD11blow cells is similar to the HSC/
HPC population; therefore, we speculated that CD11blow 
cells contribute to the maturation of blood vessels, such as 
nonleaky blood vessels. Thus, we compared the expression of 
VEGF and Ang-1 in CD11bhigh cells and CD11blow cells. As 
expected, the CD11blow cells as well as the HSC population 
had high levels of expression of Ang-1, but CD11bhigh cells 
did not (Fig. 7 a). Indeed, the expression level of Ang-1 in 
CD11blow cells was  10 times higher than in CD11bhigh cells 
by quantitative RT-PCR analysis (not depicted). Conversely, 
higher expression of VEGF was detected in CD11bhigh cells 
compared with CD11blow cells.
We then investigated the eff  ect of injection of CD11bhigh 
or CD11blow cells on the dermis of the animals. There was 
edema in the dermis of the hypoxia-induced mice injected 
with CD11bhigh cells (Fig. 7 b). In contrast, such edema was 
not observed in mice injected with CD11blow cells (Fig. 7, 
c and e). As expected, injection of CD11blow cells from Ang-1 
mutant mice (Fig. S4, available at http://www.jem.org/cgi/
content/full/jem.20050373/ DC1; reference 9) could not 
prevent edema (Fig. 7, d and e), although the CD11blow cells 
could incorporate into the wall of blood vessels (Fig. S4). 
Additionally, the edema observed in limbs injected with 
CD11bhigh cells was suppressed by simultaneous injection 
with CD11blow cells (not depicted).
Next, we confi  rmed that the leakiness of blood vessels 
induced by tail vein injection of lectin into mice increased 
in the mice injected with CD11bhigh cells (Fig. 7 f), but not 
in mice that received CD11blow cells (Fig. 7 g) in the hind 
limb ischemia model. Such a benefi  cial eff  ect of CD11blow 
cells from wild-type animals was not observed by the in-
jection of CD11blow cells from Ang-1 mutants (Fig. 7 h). 
Although CD11blow cells and CD11bhigh cells can contribute 
Figure 6.  Development of CD45+CD11b+ cells into ECs and MCs 
in newly developed blood vessels of ischemic thigh muscles. Differ-
entiation into ECs (A) or MCs (B) of CD45+CD11b− or CD45+CD11b+ cells 
injected into ischemic thigh muscles as described in Fig. 4 was observed 
using laser-scanning confocal microscopy. (A) Section from a thigh mus-
cle injected with CD45+CD11b+ (a–c) or CD45+CD11b− (d–f) cells from 
green mice. (a and d) GFP (green), (b and e) anti-CD31 mAb (red), (c) 
merged images of panels a and b, (f) merged image of panels d and e. 
Arrowheads indicate GFP+CD31+ ECs. Insets show high power view of 
area indicated by box. Bar, 50 μm. (B) Section from a thigh muscle in-
jected with CD45+CD11b+ (a–c) or CD45+CD11b− (d–f) cells from green 
mice. (a and d) GFP (green), (b and e) anti-PDGFRβ mAb (red), (c) merged 
image of panels a and b, (f) merged image of panels d and e. Arrowheads 
indicate GFP+PDGFRβ+ MCs. Insets show high power view of area indi-
cated by box. Bar, 50 μm. (C) Development of CD11bhigh or CD11blow cells 
into vascular cell in the ischemic thigh muscle at 2 wk (wk.s) or 6 mo 
(mo.s) after injection of cells. Percentage of vascular cells originating from 
CD11bhigh or CD11blow cells was expressed as percentage of total capillaries 
counted in 30 random fi  elds. In brief, when the GFP signal was detected 
in a cross section of a capillary as seen in the insets of A (a–c), this capil-
lary was counted as being formed by the injected cells.1062  VESSEL MATURATION BY HEMATOPOIETIC CELLS | Yamada and Takakura
to vascular cells similarly, these data suggest that blood   vessel 
maturation might be more eff  ectively induced by CD11blow 
cells by the ability to diff  erentiate into MCs, long-term sur-
vival after diff  erentiation into MCs, and inhibition of leaki-
ness through Ang-1.
DISCUSSION
In this study, we found that HSCs or CD11blow cells played 
critical roles in promoting stable blood vessel formation by 
their diff  erentiation into MCs and by the production of Ang-1 
in both physiological and pathological conditions. Although 
it has been reported that ECs are developed from HSC pop-
ulations through the monocyte lineage (27, 28), we found 
that MCs are also diff  erentiated from the hematopoietic lin-
eage through the same pathway as ECs by using CD45 and 
CD11b, well-known specifi  c markers expressed on HCs and 
the monocyte/macrophage lineage, respectively. In particu-
lar, we showed diff  erences between CD11blow cells and 
CD11bhigh cells in blood vessel formation. One such diff  er-
ence was that CD11low cells have a long-term regeneration 
capacity for neovascularization by diff  erentiating into ECs 
and MCs, but CD11bhigh cells do not. The other is that 
CD11bhigh cells induced the formation of leaky blood vessels, 
but CD11blow cells did not. Thus, CD11blow cells might pro-
mote the stability of newly developed blood vessels.
Progenitor cells for ECs or MCs have been suggested to 
exist in adult BM, and several reports have suggested that 
these cells develop into endothelial progenitor cells (EPCs) 
in the neovascularization of tumors and ischemic regions 
(34, 35). Moreover, the HSC population in the adult BM 
was reported to incorporate into blood vessels as MCs in ath-
erosclerotic plaques and in transplanted hearts. Sata et al. (20) 
suggested that vascular SMC progenitors also originated from 
the Lin−c-Kit+Sca-1+ HSC population. At the moment, it is 
not clear whether single Lin−c-Kit+Sca-1+ cells can give rise 
to the three diff  erent cell types, namely, HCs, ECs, and MCs. 
However, in this study, we showed that the latter two popu-
lations develop from the HC lineage by using CD45 as a 
marker expressed on HCs but not on ECs nor MCs.
Although CD11b+ cells could give rise to MCs as well as 
ECs, there were diff  erences between CD11bhigh and CD11blow 
cells. CD11bhigh cells rapidly diff  erentiated into CD31+ EC-like 
cells in vitro and were found to incorporate into newly de-
veloped blood vessels as ECs in an in vivo ischemia model. 
However, they showed low frequency for diff  erentiation 
into MCs and ECs, and MCs from CD11bhigh cells could not 
survive for the long term, both in vitro and in vivo. In con-
trast, although CD11blow cells took more time for their dif-
ferentiation into ECs, they diff  erentiated into MCs with high 
frequency. Both MCs and ECs from CD11blow cells could 
form vascular cells for the long term.
In the course of angiogenesis, vessel regression is part of 
the maturation process. Indeed, the number of newly devel-
oped blood vessels induced by CD11b+ cells gradually 
Figure 7.  Comparison of permeability of blood vessels in animals 
injected with CD11blow and CD11bhigh cells. (a) RT-PCR analysis of 
Ang-1 or VEGF-A expression in several hematopoietic lineages. Lane 1, 
CD45+Lin+ cells; lane 2, CD45+Lin− cells; lane 3, CD45+CD11bhigh cells; 
lane 4, CD45+CD11blow cells; lane 5, CD45+CD11blow cells from Ang-1 
mutants; lane 6, distilled water; lane 7, Lin−c-Kit+Sca-1+ cells in BM. 
(b–h) Mice in which ischemia was induced by the occlusion of the femoral 
artery were treated with CD11blow or CD11bhigh cells sorted as described in 
Fig. 3 A or Fig. S4. (b–d) Hematoxylin and eosin staining of skin near the 
limb 7 d after injection with CD11bhigh (b), CD11blow (c), and CD11blow 
cells from Ang-1 mutants (d). Arrows in panels b and d indicate edema-
tous space. Bar, 500 μm. (e) Thickness of the dermal and epidermal layers 
after treatment with CD11bhigh or CD11blow cells. Thickness of the dermal 
and epidermal layers of the limbs was measured at a distance of 1 cm 
from the knee and compared with that in mice treated with PBS or with 
sham (S)-operated mice. Results are expressed as the mean ± SD (n = 5). 
*, P < 0.02. (f–h) Leakage site in thigh muscle microvessels stained by 
perfusion of lectin (ricin) after injection of CD11bhigh (f), CD11blow (g), and 
CD11blow cells from Ang-1 mutants (h). Arrows indicate the exposed base-
ment membrane, which shows vascular leaks.JEM VOL. 203, April 17, 2006  1063
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decreased between 2 wk and 6 mo. In the case of CD11bhigh 
cell injection, capillary density after 6 mo was  70% of that 
present after 2 wk. On the other hand, in the case of CD11low 
cells, the capillary density was  80% at 6 mo compared with 
that present at 2 wk. It is not clear whether this higher loss 
of capillary density associated with CD11bhigh cells refl  ects 
higher apoptosis in vivo of ECs generated by CD11bhigh cells 
or not; however, this is possible because ECs generated by 
CD11high cells declined because of apoptosis after 2 wk in 
  vitro (Fig. S2).
Recently, two groups independently reported that there 
were two populations of cells with the capacity to diff  erenti-
ate into ECs from mononuclear cells in the PB (36, 37). They 
reported that CD14+ cells or spindle-shape cells in the PB 
diff  erentiate into ECs rapidly, and such ECs could not sur-
vive for the long term. They termed these ECs as early EPCs. 
On the other hand, ECs derived from CD14− cells or cells 
showing a cobblestone appearance grow exponentially, sur-
vive for a longer time, and are called late outgrowth ECs or 
late EPCs. Although they did not observe the diff  erentiation 
of MCs from EPCs, we assume that the former corresponds 
to CD11bhigh cells and the latter to CD11blow cells. Based on 
a previous report showing that cycling HSCs express CD11b 
weakly (30), CD11blow cells might belong to the HSC popu-
lation. However, the results of limiting dilution analysis 
showing low frequency of diff  erentiation of the HSC popu-
lation into ECs or MCs suggest that only a part of the imma-
ture HSC population expressing CD11b, c-Kit, and Sca-1 
can develop into vascular cells.
Additionally, we found that CD11bhigh cells induced hy-
perpermeability in this ischemia model, but CD11blow cells 
did not. In terms of leakiness of blood vessels, Ang-1 pro-
duced from MCs has been suggested to induce structurally 
stable blood vessels by promoting adhesion between MCs 
and ECs (9). Relative to this, it has been reported that VEGF-
mediated hyperpermeability can be suppressed by Ang-1 
(33). As far as we observed, CD11blow cells, but not CD11bhigh 
cells, express Ang-1 abundantly, but both CD11blow and 
CD11bhigh cells express VEGF. We previously reported that 
the HSC population produces Ang-1 strongly and promotes 
the remodeling of blood vessels during embryogenesis (19). 
Moreover, we recently reported that the CD45+c-Kit+ HSC 
population regulates caliber change and remodeling of blood 
vessels located in the fi  brous cap of a murine tumor model 
(38). Collectively, the data strongly suggest that the CD11blow 
population contains higher amounts of HSCs and promotes 
remodeling and stability of newly developed blood vessels 
along with their diff  erentiated MCs as well as the main tenance 
of Ang-1 production. Recently, there has been interest in the 
regeneration of blood vessels in ischemic patients using the 
transplantation of BM cells (39). Our analysis shows that 
  selective injection of BM HSC populations may be   eff  ective 
in achieving blood vessel regeneration.
Although several studies have shown the plasticity of 
HSCs, the problem of autonomous cell fusion between HSCs 
and tissue-specifi  c cells has been considered (40, 41). When 
the HSC population diff  erentiates into another lineage ex-
cept hematopoietic lineage during embryogenesis or other 
physiological situations, we consider those events as the natu-
ral course of the diff  erentiation pathway in the HSC popula-
tion. Here we showed that the HSC population in the brain 
during embryogenesis easily diff  erentiates into MCs as well as 
ECs. Moreover, coculturing of HSCs from the fetal liver 
with cells from the brains of embryos is necessary for the dif-
ferentiation of the HSC population from the fetal liver into 
vascular cells. This is the fi  rst report showing that the HSC 
population can change their pathway of diff  erentiation to 
something other than the hematopoietic lineage by receiving 
adequate molecular cues depending on the tissue demands, 
such as development and ischemia. Therefore, we propose 
that diff  erentiation of vascular cells from the HSC population 
runs a physiologically natural course rather than being attrib-
uted to plasticity of the cells. At this moment, the molecular 
mechanism whereby the HSC population diff  erentiates into 
MCs as well as ECs is not fully understood. Among various 
cytokines, we found that TGF-β has a weak capacity for 
changing the fate of the HSC population into MCs. In the 
present therapeutic approach to angiogenesis, larger and more 
structurally stable blood vessel formation, the so-called arte-
riogenesis, is thought to be important as a new strategy. To 
address this issue, MC management is essential. In this study, 
we could generate MC progenitors from the BM HSC pop-
ulation (Figs. S5 and S6, available at http://www.jem.org/
cgi/content/full/jem.20050373/DC1), although effi   ciency 
was low. Therefore, the use of molecules that are eff  ective in 
promoting MC development from HSCs may enable the 
  realization of the arteriogenesis goal.
MATERIALS AND METHODS
Animals. C57BL/6 mice were purchased from Japan SCL. AML1 mutant 
mice (22) were provided by T. Watanabe (Tohoku University, Sendai, 
  Japan), green mice that express GFP ubiquitously (23) were provided by M. 
Okabe (Osaka University, Osaka, Japan), and Ang-1 mutant mice (33) were 
provided by G.D. Yancopoulos (Regeneron Pharmaceuticals Inc). Animals 
were housed in environmentally controlled rooms of the animal experimen-
tation facility at Kanazawa University under the guidelines of the Kanazawa 
University Committee for Animal and Recombinant DNA Experiments.
Immunohistochemistry. Immunohistochemical analyses on tissue sec-
tions were performed as described previously (19). The tissue fi  xation pro-
cedures were the same as those described previously (42). The fi  xed specimens 
were embedded in OCT compound and sectioned at 7 μm. The following 
antibody preparations and conjugates were used: anti-CD31 antibody, 
CD31-biotin (BD Biosciences), anti–c-Kit–biotin (BD Biosciences), 
anti–VEGFR-2–biotin (BD Biosciences), anti-CD140b antibody (anti-
PDGF receptor β; BD Biosciences), and horseradish peroxidase (HRP)-
conjugated anti-SMA antibody (Sigma-Aldrich).
In brief, biotinylated anti-CD31, anti–VEGFR-2, and anti–c-kit anti-
bodies were detected by reaction with alkaline phosphatase (ALP)-conju-
gated streptavidin ABC complex (DakoCytomation), and anti-CD31 and 
anti-PDGF receptor β antibodies were detected with HRP-conjugated 
goat anti–rat Igs (Biosource). Diaminobenzidine (DAB; Dojin Chemicals) 
was used for the HRP color reaction. Fuchsin (New Fuchsin substrate sys-
tem; DakoCytomation) or 5-bromo-4-chloro-3-indoxyl phosphate/nitro 
blue tetrazolium chloride (BCIP/NBT; DakoCytomation) was used for the 
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anti–VEGFR-2–biotin, HRP-conjugated anti-SMA, anti–CD31-PE (BD 
Biosciences), anti–SMA-Cy3 (Sigma-Aldrich), and anti-GFP (Medical Bio-
logical Laboratories Co., Inc.) antibodies were used. Anti–CD31-biotin and 
anti–VEGFR-2–biotin antibodies were detected with ALP-conjugated 
streptavidin ABC complex (DakoCytomation), and anti-GFP antibody was 
detected with Alexa Fluor 488–conjugated goat anti–rabbit IgG (Invitro-
gen). ALP color was developed as described above.
The stained sections and dishes were observed and photographed with 
a microscope (IX-70; Olympus) under UV light or with a confocal micro-
scope (LSM510; Carl Zeiss MicroImaging, Inc.). In all assays, we used an 
isotype-matched control Ig as a negative control and confi  rmed that the sig-
nals were specifi  c and were not due to nonspecifi  c background staining.
Cell preparation and fl  ow cytometry. The fetal liver and head region of 
embryos at embryonic day 12.5 (E12.5) were dissociated by Dispase II 
(Boehringer) and drawn through a 23G needle. BM cells were collected 
from the tibiae and femurs, and PB was collected from the axillary vein using 
standard methods. The mononuclear cells were isolated by centrifugation 
from total BM cells or PB on Lymphoprep (AXIS-SHIELD PoC AS) ac-
cording to the manufacturer’s instructions. The cell-staining procedure for 
the fl  ow cytometry was as described previously (10). The mAbs used in im-
munofl   uorescence staining were anti-CD45, anti–c-kit, and anti-lineage 
(a mixture of ter119, Gr-1, Mac-1, B220, CD4, and CD8) antibodies (all 
purchased from BD Biosciences). All mAbs were purifi  ed and conjugated 
with either FITC, PE, or biotin. Biotinylated antibodies were visualized 
with PE-conjugated streptavidin or APC-conjugated streptavidin (BD 
  Biosciences). Cells were incubated for 5 min on ice with a 1:100 dilution of 
CD16/32 (FcγIII/II Receptor [Fcblock]; BD Biosciences) before staining 
with primary antibody. Staining procedures were as described previously 
(19). The stained cells were analyzed and sorted by an EPICS fl  ow cyto-
meter (ALTRA; Beckman Coulter).
Cell cultures. 104 sorted HSCs from E12.5 fetal liver or the head region 
were cultured for 14 d on fi  bronectin-coated dishes (Becton Dickinson) in 
EBM-2 medium (Clonetics) supplemented with 10 ng/ml VEGF (Pepro-
Tech) or 10 ng/ml PDFB-BB (PeproTech). 104 HSCs from fetal liver 
(E12.5) were cocultured with 106 cells from the brain (E12.5) in EBM-2 
medium separated by a transwell membrane (pore size 0.4 μm; Becton 
Dickinson) for 14 d. For the coculture, the EBM-2 medium was supple-
mented with EGM-2-MV-SingleQuots (Clonetics) containing VEGF, IGF-1, 
EGF, PDGF-BB, and 5% FBS at 37°C in a 5% CO2 incubator for 14 d.
105 sorted PB cells from mice with hind limb ischemia were cultured on 
fi  bronectin-coated dishes in EBM-2 medium supplemented with EGM-2-
MV-SingleQuots (Clonetics) at 37°C in a 5% CO2 incubator for 7–28 d. For 
limiting dilution analysis, isolated CD11blow and CD11bhigh cells were cul-
tured as described above and seeded in 96-well plates at several dilutions, 
with 16 replicate wells for each. Wells that did not contain ECs or MCs were 
confi  rmed by immunostaining with anti–PECAM-1 or anti-SMA mAbs 
  after 2 wk of culture by counting the positively stained cells. The number of 
ECs or MCs was determined by using Poisson distribution. Twice a week, 
one third of the culture medium was removed and replaced with fresh 
  medium containing growth factors.
Mouse model of hind limb ischemia and cell implantation. All surgi-
cal procedures were performed as described previously (43). In brief, the re-
cipient mice were anesthetized, and ligation and resection of the left femoral 
artery and vein were performed. After 3 d, 2 × 105 sorted CD11b+, CD11blow, 
CD11bhigh, or CD11b− cells from the PB of ischemia-induced green mice 
were suspended in 50 μl PBS and implanted into the ischemic thigh muscle 
of mice at fi  ve diff  erent injection points. 3 × 105 CD11blow, CD11bhigh, or 
CD11b− cells sorted as described above were suspended in 100 μl PBS and 
injected intravenously via the tail vein into ischemia-induced C57BL/6 
mice. The thigh muscles were dissected out 3 d, 14 d, or 6 mo after trans-
plantation. Tissue staining with anti-GFP (Medical Biological Laboratories 
Co., Inc.), CD31, CD31-PE (BD Biosciences), and PDGF-β-PE was 
  performed as described above to evaluate the localization of injected 
GFP+ cells and the number of ECs and SMCs.
Staining of blood vessels with lectin in ischemic hind limbs. Lec-
tin staining was performed as described previously with some modifi  ca-
tions (44). In brief, 3 d after cell transplantation, mice were perfused with 
2% paraformaldehyde to fi  x the tissue. After fi  xation, blocking was per-
formed with 1% BSA followed with perfusion with biotinylated lectin 
(20 μg/ml). The muscles were then removed and sectioned at 200 μm by 
Vibratome 1500 (The Vibratome Company). To localize the lectin bind-
ing, samples were incubated at 4°C overnight with streptavidin HRP 
(DakoCytomation). Color reaction was performed with 0.05% 3,3′-
  diaminobenzidine (DAB; Wako) and 0.01% H2O2 in Tris buff  er, pH 7.4, 
at room temperature. After the color reaction, samples were washed 
thoroughly with PBS and cleared in BABB solution (benzyl alcohol/ 
benzyl benzoate/methanol; 1:2:1).
Online supplemental material. The online supplemental material con-
tains detailed information regarding the analysis of vascular-specifi  c marker 
expression in cultured ECs and MCs (Fig. S1), detection of apoptotic cells in 
cultured ECs (Fig. S2), localization of endogenous CD11b+ cells recruited 
into ischemic muscle (Fig. S3), analysis of CD11blow cell development from 
Ang-1 mutant embryos (Fig. S4), in vitro manipulation of CD11blow cells 
from adult mouse BM (Figs. S5 and S6), in vitro CFU-c analysis (Table S1), 
and RT-PCR analysis (Table S2). The online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20050373/DC1.
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